Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 89

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 89
---
 carried forward                                                              
                                                     Gross losses                  Potential                 
  31 December 2024                                                     79,740                        19,935  
  31 December 2023                                                     75,530                        18,947  
  31 December 2022                                                     71,139                        17,867  

The potential deferred tax asset of
£19.9million (2023: £18.9million, 2022: £17.9million) has not been provided in these accounts due to uncertainty
as to whether the asset would be recovered. The losses have arisen as a result of accumulated trading losses.

Deferred tax asset balances disclosed
as at 31 December 2024 have been calculated at 25%. The main rate of corporation tax increased to 25% from 1 April 2023.

22 Share
capital

  Schedule of detailed information about share capital                                                                                                       
  Authorised, allotted and                                                                                                                                   
  At 31 December                                                                                                                                             
  Ordinary shares of                                          6,685,918,922         334,296      1,189,577,722      1,189,578      5,417,137      108,343    
  ‘ A’ Deferred shares of £1 each                                 1,000,001       1,000,001          1,000,001      1,000,001      1,000,001      1,000,001  
  ‘ B’ Deferred shares of £0.001 each                         4,063,321,418       4,063,321      4,063,321,418      4,063,321      –              –          
  ‘ C’ Deferred shares of £0.00005 each                     126,547,389,518       6,327,370                  –              –      –              –          
  Total                                                                          11,724,988                         6,252,900                     1,108,344  

At a General Meeting on 22 November
2024, shareholders approved the subdivision and redesignation of the Company’s Issued Ordinary Shares of £0.001 each into
to one Ordinary Share of £0.00005 each and 19 ‘ C’ Deferred Shares of £0.00005 each. The ‘ C’ Deferred
Shares have limited rights and are effectively valueless.

On 22 July 2024 the Company entered
into Registered Direct Offering, as insufficient share premium was recognised in